1 Madhusoodhan, P. P., Carroll, W. L. & Bhatla, T. Progress and Prospects in Pediatric Leukemia. Current problems in pediatric and adolescent health care 46, 229-241, doi:10.1016/j.cppeds.2016.04.003 (2016).
2 Lonetti, A., Pession, A. & Masetti, R. Targeted Therapies for Pediatric AML: Gaps and Perspective. Frontiers in pediatrics 7, 463, doi:10.3389/fped.2019.00463 (2019).
3 van Eys, J. et al. The French-American-British (FAB) classification of leukemia. The Pediatric Oncology Group experience with lymphocytic leukemia. Cancer 57, 1046-1051, doi:10.1002/1097-0142(19860301)57:5<1046::aid-cncr2820570529>3.0.co;2-0 (1986).
4 Tallman, M. S. et al. Acute monocytic leukemia (French-American-British classification M5) does not have a worse prognosis than other subtypes of acute myeloid leukemia: a report from the Eastern Cooperative Oncology Group. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 22, 1276-1286, doi:10.1200/jco.2004.08.060 (2004).
5 Liu, L. P. et al. Prognostic stratification of molecularly and clinically distinct subgroup in children with acute monocytic leukemia. doi:10.1002/cam4.3023 (2020).
6 Tsuchiya, S. et al. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). International journal of cancer 26, 171-176, doi:10.1002/ijc.2910260208 (1980).
7 Odero, M. D., Zeleznik-Le, N. J., Chinwalla, V. & Rowley, J. D. Cytogenetic and molecular analysis of the acute monocytic leukemia cell line THP-1 with an MLL-AF9 translocation. Genes, chromosomes & cancer 29, 333-338 (2000).
8 Hu, Z. D. et al. Gene expression profile of THP-1 cells treated with heat-killed Candida albicans. Ann Transl Med 4, 170, doi:10.21037/atm.2016.05.03 (2016).
9 Chanput, W., Mes, J. J. & Wichers, H. J. THP-1 cell line: an in vitro cell model for immune modulation approach. International immunopharmacology 23, 37-45, doi:10.1016/j.intimp.2014.08.002 (2014).
10 Suzuki, S., Nakano, H. & Takahashi, S. Epigenetic regulation of the metallothionein-1A promoter by PU.1 during differentiation of THP-1 cells. Biochemical and biophysical research communications 433, 349-353, doi:10.1016/j.bbrc.2013.03.007 (2013).
11 Davis, F. M. & Gallagher, K. A. Epigenetic Mechanisms in Monocytes/Macrophages Regulate Inflammation in Cardiometabolic and Vascular Disease. Arteriosclerosis, thrombosis, and vascular biology 39, 623-634, doi:10.1161/atvbaha.118.312135 (2019).
12 Hoeksema, M. A. & de Winther, M. P. Epigenetic Regulation of Monocyte and Macrophage Function. Antioxidants & redox signaling 25, 758-774, doi:10.1089/ars.2016.6695 (2016).
13 Ciavatta, D. J. et al. Epigenetic basis for aberrant upregulation of autoantigen genes in humans with ANCA vasculitis. The Journal of clinical investigation 120, 3209-3219, doi:10.1172/jci40034 (2010).
14 Gan, L. et al. Epigenetic regulation of cancer progression by EZH2: from biological insights to therapeutic potential. 6, 10, doi:10.1186/s40364-018-0122-2 (2018).
15 Wang, W. et al. Polycomb Group (PcG) Proteins and Human Cancers: Multifaceted Functions and Therapeutic Implications. Medicinal research reviews 35, 1220-1267, doi:10.1002/med.21358 (2015).
16 Chan, H. L. & Morey, L. Emerging Roles for Polycomb-Group Proteins in Stem Cells and Cancer. Trends in biochemical sciences 44, 688-700, doi:10.1016/j.tibs.2019.04.005 (2019).
17 Pasini, D. & Di Croce, L. Emerging roles for Polycomb proteins in cancer. Current opinion in genetics & development 36, 50-58, doi:10.1016/j.gde.2016.03.013 (2016).
18 Varambally, S. et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 419, 624-629, doi:10.1038/nature01075 (2002).
19 Raaphorst, F. M. et al. Poorly differentiated breast carcinoma is associated with increased expression of the human polycomb group EZH2 gene. Neoplasia (New York, N.Y.) 5, 481-488, doi:10.1016/s1476-5586(03)80032-5 (2003).
20 Croonquist, P. A. & Van Ness, B. The polycomb group protein enhancer of zeste homolog 2 (EZH 2) is an oncogene that influences myeloma cell growth and the mutant ras phenotype. Oncogene 24, 6269-6280, doi:10.1038/sj.onc.1208771 (2005).
21 Zhang, P. et al. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer. Cell reports 23, 823-837, doi:10.1016/j.celrep.2018.03.078 (2018).
22 Wang, J. et al. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. The Journal of clinical investigation 127, 3075-3089, doi:10.1172/jci89092 (2017).
23 Yang, P. M., Hong, Y. H., Hsu, K. C. & Liu, T. P. p38α/S1P/SREBP2 activation by the SAM-competitive EZH2 inhibitor GSK343 limits its anticancer activity but creates a druggable vulnerability in hepatocellular carcinoma. American journal of cancer research 9, 2120-2139 (2019).
24 Huang, K. et al. A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells. Cell cycle (Georgetown, Tex.) 19, 758-771, doi:10.1080/15384101.2020.1729450 (2020).
25 Yomtoubian, S. et al. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer. Cell reports 30, 755-770.e756, doi:10.1016/j.celrep.2019.12.056 (2020).
26 Jin, X. et al. CDK5/FBW7-dependent ubiquitination and degradation of EZH2 inhibits pancreatic cancer cell migration and invasion. The Journal of biological chemistry 292, 6269-6280, doi:10.1074/jbc.M116.764407 (2017).
27 Xue, H. et al. Oncogene, doi:10.1038/s41388-019-1132-8.
28 Wang, Q. et al. Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin. Journal of molecular cell biology 12, 125-137, doi:10.1093/jmcb/mjz032 (2020).
29 Ciarapica, R., Miele, L., Giordano, A., Locatelli, F. & Rota, R. Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first implications. BMC Medicine 9, 63, doi:10.1186/1741-7015-9-63 (2011).
30 Venneti, S. et al. Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain pathology (Zurich, Switzerland) 23, 558-564, doi:10.1111/bpa.12042 (2013).
31 Basheer, F. & Giotopoulos, G. Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML. 216, 966-981, doi:10.1084/jem.20181276 (2019).
32 Mechaal, A., Menif, S., Abbes, S. & Safra, I. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients. Advances in medical sciences 64, 395-401, doi:10.1016/j.advms.2019.07.002 (2019).
33 Al-Ghabkari, A. & Narendran, A. In Vitro Characterization of a Potent p53-MDM2 Inhibitor, RG7112 in Neuroblastoma Cancer Cell Lines. Cancer biotherapy & radiopharmaceuticals 34, 252-257, doi:10.1089/cbr.2018.2732 (2019).
34 Al-Ghabkari, A. et al. A novel inhibitory effect of oxazol-5-one compounds on ROCKII signaling in human coronary artery vascular smooth muscle cells. Scientific reports 6, 32118, doi:10.1038/srep32118 (2016).
35 Huet, S. et al. EZH2 alterations in follicular lymphoma: biological and clinical correlations. Blood cancer journal 7, e555, doi:10.1038/bcj.2017.32 (2017).
36 Akpa, C. A. et al. DZNep-mediated apoptosis in B-cell lymphoma is independent of the lymphoma type, EZH2 mutation status and MYC, BCL2 or BCL6 translocations. PloS one 14, e0220681, doi:10.1371/journal.pone.0220681 (2019).
37 Yu, T. et al. The EZH2 inhibitor GSK343 suppresses cancer stem-like phenotypes and reverses mesenchymal transition in glioma cells. Oncotarget 8, 98348-98359, doi:10.18632/oncotarget.21311 (2017).
38 Girard, N. et al. 3-Deazaneplanocin A (DZNep), an inhibitor of the histone methyltransferase EZH2, induces apoptosis and reduces cell migration in chondrosarcoma cells. PloS one 9, e98176, doi:10.1371/journal.pone.0098176 (2014).
39 Huang, S. et al. EZH2 inhibitor GSK126 suppresses anti-tumor immunity by driving production of myeloid-derived suppressor cells. Cancer Research, canres.2395.2018, doi:10.1158/0008-5472.CAN-18-2395 (2019).
40 Qi, W. et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proceedings of the National Academy of Sciences of the United States of America 109, 21360-21365, doi:10.1073/pnas.1210371110 (2012).
41 Lindsay, C. D. et al. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas. 9, 95, doi:10.1186/s13148-017-0390-y (2017).
42 Konze, K. D. et al. An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. ACS chemical biology 8, 1324-1334, doi:10.1021/cb400133j (2013).
43 Knutson, S. K. et al. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. Molecular cancer therapeutics 13, 842-854, doi:10.1158/1535-7163.mct-13-0773 (2014).
44 Zingg, D. et al. The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors. Nature communications 6, 6051, doi:10.1038/ncomms7051 (2015).
45 Greer, E. L. & Shi, Y. Histone methylation: a dynamic mark in health, disease and inheritance. Nature reviews. Genetics 13, 343-357, doi:10.1038/nrg3173 (2012).
46 Zeng, D., Liu, M. & Pan, J. Blocking EZH2 methylation transferase activity by GSK126 decreases stem cell-like myeloma cells. Oncotarget 8, 3396-3411, doi:10.18632/oncotarget.13773 (2017).
47 Adhikary, G. et al. Survival of skin cancer stem cells requires the Ezh2 polycomb group protein. Carcinogenesis 36, 800-810, doi:10.1093/carcin/bgv064 (2015).
48 Grinshtein, N. et al. Small molecule epigenetic screen identifies novel EZH2 and HDAC inhibitors that target glioblastoma brain tumor-initiating cells. Oncotarget 7, 59360-59376, doi:10.18632/oncotarget.10661 (2016).
49 Dhillon, A. S., Hagan, S., Rath, O. & Kolch, W. MAP kinase signalling pathways in cancer. Oncogene 26, 3279-3290, doi:10.1038/sj.onc.1210421 (2007).
50 Porta, C., Paglino, C. & Mosca, A. Targeting PI3K/Akt/mTOR Signaling in Cancer. Frontiers in oncology 4, 64, doi:10.3389/fonc.2014.00064 (2014).
51 Al-Ghabkari, A., Perinpanayagam, M. A. & Narendran, A. Inhibition of PI3K/mTOR pathways with GDC-0980 in pediatric leukemia: Impact on abnormal FLT-3 activity and cooperation with intracellular signaling targets. Current cancer drug targets, doi:10.2174/1568009619666190326120833 (2019).
52 Sugimoto, K. et al. Frequent mutations in the p53 gene in human myeloid leukemia cell lines. Blood 79, 2378-2383 (1992).
53 Yardley, D. A. Drug resistance and the role of combination chemotherapy in improving patient outcomes. International journal of breast cancer 2013, 137414, doi:10.1155/2013/137414 (2013).
54 Al-Ghabkari, A., Perinpanayagam, M. A. & Narendran, A. Inhibition of PI3K/mTOR Pathways with GDC-0980 in Pediatric Leukemia: Impact on Abnormal FLT-3 Activity and Cooperation with Intracellular Signaling Targets. Current cancer drug targets 19, 828-837, doi:10.2174/1568009619666190326120833 (2019).
55 Walker, C. J. et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias. Blood 122, 3034-3044, doi:10.1182/blood-2013-04-495374 (2013).
56 Kuruvilla, J. et al. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma. Blood 129, 3175-3183, doi:10.1182/blood-2016-11-750174 (2017).
57 Gounder, M. M. et al. Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 34, 3166-3174, doi:10.1200/jco.2016.67.6346 (2016).
58 Bahlis, N. J. et al. Selinexor plus low-dose bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma. Blood 132, 2546-2554, doi:10.1182/blood-2018-06-858852 (2018).
59 Wang, A. Y. et al. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of hematology & oncology 11, 4, doi:10.1186/s13045-017-0550-8 (2018).
60 Kim, K. H. & Roberts, C. W. M. Targeting EZH2 in cancer. Nat Med 22, 128-134, doi:10.1038/nm.4036 (2016).
61 McCabe, M. T. et al. Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27). Proceedings of the National Academy of Sciences of the United States of America 109, 2989-2994, doi:10.1073/pnas.1116418109 (2012).
62 Kim, K. H. & Roberts, C. W. Targeting EZH2 in cancer. Nat Med 22, 128-134, doi:10.1038/nm.4036 (2016).
63 Christofides, A., Karantanos, T., Bardhan, K. & Boussiotis, V. A. Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2. Oncotarget 7, 85624-85640, doi:10.18632/oncotarget.12928 (2016).
64 Tabbal, H. et al. EZH2 cooperates with E2F1 to stimulate expression of genes involved in adrenocortical carcinoma aggressiveness. British journal of cancer 121, 384-394, doi:10.1038/s41416-019-0538-y (2019).
65 Papale, M. et al. EZH2, HIF-1, and Their Inhibitors: An Overview on Pediatric Cancers. Frontiers in pediatrics 6, 328, doi:10.3389/fped.2018.00328 (2018).
66 Song, X. et al. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 81, 288-294, doi:10.1016/j.biopha.2016.04.019 (2016).
67 Villanueva, M. T. Anticancer drugs: All roads lead to EZH2 inhibition. Nature reviews. Drug discovery 16, 239, doi:10.1038/nrd.2017.55 (2017).
68 Bradley, W. D. et al. EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. Chemistry & biology 21, 1463-1475, doi:10.1016/j.chembiol.2014.09.017 (2014).
69 Ozes, A. R. et al. Protein kinase A-mediated phosphorylation regulates STAT3 activation and oncogenic EZH2 activity. Oncogene 37, 3589-3600, doi:10.1038/s41388-018-0218-z (2018).
70 Chen, S. et al. Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nature cell biology 12, 1108-1114, doi:10.1038/ncb2116 (2010).
71 Bott, S. R., Arya, M., Kirby, R. S. & Williamson, M. p21WAF1/CIP1 gene is inactivated in metastatic prostatic cancer cell lines by promoter methylation. Prostate cancer and prostatic diseases 8, 321-326, doi:10.1038/sj.pcan.4500822 (2005).
72 Askari, M., Sobti, R. C., Nikbakht, M. & Sharma, S. C. Aberrant promoter hypermethylation of p21 (WAF1/CIP1) gene and its impact on expression and role of polymorphism in the risk of breast cancer. Molecular and cellular biochemistry 382, 19-26, doi:10.1007/s11010-013-1696-5 (2013).
73 Zhu, J., Dou, Z., Sammons, M. A., Levine, A. J. & Berger, S. L. Lysine methylation represses p53 activity in teratocarcinoma cancer cells. Proceedings of the National Academy of Sciences of the United States of America 113, 9822-9827, doi:10.1073/pnas.1610387113 (2016).
74 Ito, T. et al. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas. Journal of gastroenterology 39, 355-361, doi:10.1007/s00535-003-1302-9 (2004).
75 Yi, L., Sun, Y. & Levine, A. Selected drugs that inhibit DNA methylation can preferentially kill p53 deficient cells. Oncotarget 5, 8924-8936, doi:10.18632/oncotarget.2441 (2014).
76 Fan, T. et al. EZH2-dependent suppression of a cellular senescence phenotype in melanoma cells by inhibition of p21/CDKN1A expression. Molecular cancer research : MCR 9, 418-429, doi:10.1158/1541-7786.mcr-10-0511 (2011).
77 Talati, C. & Sweet, K. L. Nuclear transport inhibition in acute myeloid leukemia: recent advances and future perspectives. International journal of hematologic oncology 7, Ijh04, doi:10.2217/ijh-2018-0001 (2018).